FOXO3-N-κB RelA protein complexes reduce proinflammatory cell signaling and function

Journal of Immunology

Volumn 195, Issue 12, 2015, Pages 5637-5647

  Thompson, Matthew G ^a   Larson, Michelle ^a   Vidrine, Amy ^a   Barrios, Kelly ^a   Navarro, Flor ^a   Meyers, Kaitlyn ^a   Simms, Patricia ^a   Prajapati, Kushal ^a   Chitsike, Lennox ^a   Hellman, Lance M ^b   Baker, Brian M ^a   Watkins, Stephanie K ^a  

^a LOYOLA UNIVERSITY HEALTH SYSTEM   (United States)

^b UNIVERSITY OF NOTRE DAME   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; TRANSCRIPTION FACTOR FKHRL1; TRANSCRIPTION FACTOR RELA; FORKHEAD TRANSCRIPTION FACTOR; FOXO3 PROTEIN, MOUSE; PROTEIN BINDING;

ARTICLE; BONE MARROW CELL; CELL ISOLATION; CELL SIGNALING ASSAY; CYTOSOL; DENDRITIC CELL; DNA BINDING; HUMAN; MACROPHAGE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; TRANSACTIVATION; ADENOCARCINOMA; ANIMAL; EXPERIMENTAL MELANOMA; GENETICS; IMMUNOLOGY; KNOCKOUT MOUSE; MALE; METABOLISM; MOLECULARLY TARGETED THERAPY; MOUSE; PROSTATE TUMOR; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION;

ADENOCARCINOMA; ANIMALS; DENDRITIC CELLS; FORKHEAD BOX PROTEIN O3; FORKHEAD TRANSCRIPTION FACTORS; MACROPHAGES; MALE; MELANOMA, EXPERIMENTAL; MICE; MICE, KNOCKOUT; MOLECULAR TARGETED THERAPY; MYELOID CELLS; NF-KAPPA B; PROSTATIC NEOPLASMS; PROTEIN BINDING; PROTEIN INTERACTION DOMAINS AND MOTIFS; SIGNAL TRANSDUCTION; TRANSCRIPTIONAL ACTIVATION;

EID: 84958292031     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1501758     Document Type: Article

References (37)

1. Tenbaum, S. P., P. Ordón-ez-Morán, I. Puig, I. Chicote, O. Arqués, S. Landolfi, Y. Fernández, J. R. Herance, J. D. Gispert, L. Mendizabal, et al. 2012. b-catenin confers resistance to PI3K and AKT inhibitors and subverts FOXO3a to promote metastasis in colon cancer. Nat. Med. 18: 892-901.
2. Zhou, F., H. Wei, A. Ding, W. Qiu, L. Feng, Q. Zhou, J. Liang, and L. Yue. 2013. Different cellular localization of NF-kB p65 expression as an indicator of different prognoses of stage I-III gastric cancer patients. Clin. Transl. Sci. 6: 381-385.
3. Watanabe, M., K. D. Moon, M. S. Vacchio, K. S. Hathcock, and R. J. Hodes. 2014. Downmodulation of tumor suppressor p53 by T cell receptor signaling is critical for antigen-specific CD4(+) T cell responses. Immunity 40: 681-691.
4. Wang, F., C. B. Marshall, K. Yamamoto, G. Y. Li, M. J. Plevin, H. You, T. W. Mak, and M. Ikura. 2008. Biochemical and structural characterization of an intramolecular interaction in FOXO3a and its binding with p53. J. Mol. Biol. 384: 590-603.
5. Huang, Y., P. Yu, W. Li, G. Ren, A. I. Roberts, W. Cao, X. Zhang, J. Su, X. Chen, Q. Chen, et al. 2014. p53 regulates mesenchymal stem cell-mediated tumor suppression in a tumor microenvironment through immune modulation. Onco-gene 33: 3830-3838.
6. Liang, X., C. Fu, W. Cui, J. L. Ober-Blöbaum, S. P. Zahner, P. A. Shrikant, B. E. Clausen, R. A. Flavell, I. Mellman, and A. Jiang. 2014. b-catenin mediates tumor-induced immunosuppression by inhibiting cross-priming of CD8? T cells. J. Leukoc. Biol. 95: 179-190.
7. Dejean, A. S., D. R. Beisner, I. L. Ch'en, Y. M. Kerdiles, A. Babour, K. C. Arden, D. H. Castrillon, R. A. DePinho, and S. M. Hedrick. 2009. Transcription factor Foxo3 controls the magnitude of T cell immune responses by modulating the function of dendritic cells. Nat. Immunol. 10: 504-513.
8. Harada, Y., Y. Harada, C. Elly, G. Ying, J. H. Paik, R. A. DePinho, and Y. C. Liu. 2010. Transcription factors Foxo3a and Foxo1 couple the E3 ligase Cbl-b to the induction of Foxp3 expression in induced regulatory T cells. J. Exp. Med. 207: 1381-1391.
9. Lee, J. C., M. Espéli, C. A. Anderson, M. A. Linterman, J. M. Pocock, N. J. Williams, R. Roberts, S. Viatte, B. Fu, N. Peshu, et al; UK IBD Genetics Consortium. 2013. Human SNP links differential outcomes in inflammatory and infectious disease to a FOXO3-regulated pathway. Cell 155: 57-69.
10. Kerdiles, Y. M., E. L. Stone, D. R. Beisner, M. A. McGargill, I. L. Ch'en, C. Stockmann, C. D. Katayama, and S. M. Hedrick. 2010. Foxo transcription factors control regulatory T cell development and function. Immunity 33: 890-904.
11. Ouyang, W., O. Beckett, Q. Ma, J. H. Paik, R. A. DePinho, and M. O. Li. 2010. Foxo proteins cooperatively control the differentiation of Foxp3+ regulatory T cells. Nat. Immunol. 11: 618-627.
12. Du, X., H. Shi, J. Li, Y. Dong, J. Liang, J. Ye, S. Kong, S. Zhang, T. Zhong, Z. Yuan, et al. 2014. Mst1/Mst2 regulate development and function of regulatory T cells through modulation of Foxo1/Foxo3 stability in autoimmune disease. J. Immunol. 192: 1525-1535.
13. Gingrich, J. R., R. J. Barrios, R. A. Morton, B. F. Boyce, F. J. DeMayo, M. J. Finegold, R. Angelopoulou, J. M. Rosen, and N. M. Greenberg. 1996. Metastatic prostate cancer in a transgenic mouse. Cancer Res. 56: 4096-4102.
14. Zhu, Z., V. Singh, S. K. Watkins, V. Bronte, J. L. Shoe, L. Feigenbaum, and A. A. Hurwitz. 2013. High-avidity T cells are preferentially tolerized in the tumor microenvironment. Cancer Res. 73: 595-604.
15. Watkins, S. K., Z. Zhu, K. E. Watkins, and A. A. Hurwitz. 2012. Isolation of immune cells from primary tumors. J. Vis. Exp. 64: e3952. Available at: http://www.jove.com/video/3952/isolation-of-immune-cells-from-primary-tumors
16. Lakowicz, J. R., M. H. Chowdhury, K. Ray, J. Zhang, Y. Fu, R. Badugu, C. R. Sabanayagam, K. Nowaczyk, H. Szmacinski, K. Aslan, and C. D. Geddes. 2006. Plasmon-controlled fluorescence: a new detection technology. Proc. SPIE Int. Soc. Opt. Eng. 6099: 609909.
17. Mou, Y., T. W. Tsai, and J. C. Chan. 2007. Determination of the backbone torsion psi angle by tensor correlation of chemical shift anisotropy and hetero-nuclear dipole-dipole interaction. Solid State Nucl. Magn. Reson. 31: 72-81.
18. Koorella, C., J. R. Nair, M. E. Murray, L. M. Carlson, S. K. Watkins, and K. P. Lee. 2014. Novel regulation of CD80/CD86-induced phosphatidylinositol 3-kinase signaling by NOTCH1 protein in interleukin-6 and indoleamine 2, 3-dioxygenase production by dendritic cells. J. Biol. Chem. 289: 7747-7762.
19. Calnan, D. R., and A. Brunet. 2008. The FoxO code. Oncogene 27: 2276-2288.
20. Yang, L., S. Xie, M. S. Jamaluddin, S. Altuwaijri, J. Ni, E. Kim, Y. T. Chen, Y. C. Hu, L. Wang, K. H. Chuang, et al. 2005. Induction of androgen receptor expression by phosphatidylinositol 3-kinase/Akt downstream substrate, FOXO3a, and their roles in apoptosis of LNCaP prostate cancer cells. J. Biol. Chem. 280: 33558-33565.
21. Karube, K., S. Tsuzuki, N. Yoshida, K. Arita, F. Liu, E. Kondo, Y. H. Ko, K. Ohshima, S. Nakamura, T. Kinoshita, and M. Seto. 2012. Lineage-specific growth inhibition of NK cell lines by FOXO3 in association with Akt activation status. Exp. Hematol. 40: 1005-1015.e6. doi:10.1016/j.exphem.2012.08.005.
22. Comel, A., G. Sorrentino, V. Capaci, and G. Del Sal. 2014. The cytoplasmic side of p53's oncosuppressive activities. FEBS Lett. 588: 2600-2609.
23. Liu, W., Y. Gong, H. Li, G. Jiang, S. Zhan, H. Liu, and Y. Wu. 2012. Arsenic trioxide-induced growth arrest of breast cancer MCF-7 cells involving FOXO3a and IkB kinase b expression and localization. Cancer Biother. Radiopharm. 27: 504-512.
24. Lakowicz, J. R. 2006. Plasmonics in biology and plasmon-controlled fluorescence. Plasmonics 1: 5-33.
25. Hsu, J. L., A. Leemans, C. H. Bai, C. H. Lee, Y. F. Tsai, H. C. Chiu, and W. H. Chen. 2008. Gender differences and age-related white matter changes of the human brain: a diffusion tensor imaging study. Neuroimage 39: 566-577.
26. Kang, M. I., C. J. Henrich, H. R. Bokesch, K. R. Gustafson, J. B. McMahon, A. R. Baker, M. R. Young, and N. H. Colburn. 2009. A selective small-molecule nuclear factor-kappaB inhibitor from a high-throughput cell-based assay for "activator protein-1 hits". Mol. Cancer Ther. 8: 571-581.
27. Ben-Neriah, Y., and M. Karin. 2011. Inflammation meets cancer, with NF-kB as the matchmaker. Nat. Immunol. 12: 715-723.
28. Kornblau, S. M., N. Singh, Y. Qiu, W. Chen, N. Zhang, and K. R. Coombes. 2010. Highly phosphorylated FOXO3A is an adverse prognostic factor in acute myeloid leukemia. Clin. Cancer Res. 16: 1865-1874.
29. Chipuk, J. E., and D. R. Green. 2004. Cytoplasmic p53: bax and forward. Cell Cycle 3: 429-431.
30. Fu, C., and A. Jiang. 2013. b-catenin-mediated inhibition of cross-priming: a new mechanism for tumors to evade immunosurveillance. OncoImmunology 2: e26920.
31. Brunet, A., A. Bonni, M. J. Zigmond, M. Z. Lin, P. Juo, L. S. Hu, M. J. Anderson, K. C. Arden, J. Blenis, and M. E. Greenberg. 1999. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 96: 857-868.
32. del Peso, L., V. M. González, R. Hernández, F. G. Barr, and G. Nún-ez. 1999. Regulation of the forkhead transcription factor FKHR, but not the PAX3-FKHR fusion protein, by the serine/threonine kinase Akt. Oncogene 18: 7328-7333.
33. Ring, S., M. Maas, D. M. Nettelbeck, A. H. Enk, and K. Mahnke. 2013. Targeting of autoantigens to DEC205? dendritic cells in vivo suppresses experimental allergic encephalomyelitis in mice. J. Immunol. 191: 2938-2947.
34. Burslem, G. M., H. F. Kyle, A. L. Breeze, T. A. Edwards, A. Nelson, S. L. Warriner, and A. J. Wilson. 2014. Small-molecule proteomimetic inhibitors of the HIF-1a-p300 protein-protein interaction. ChemBioChem 15: 1083-1087.
35. Gogate, P. N., M. Ethirajan, E. V. Kurenova, A. T. Magis, R. K. Pandey, and W. G. Cance. 2014. Design, synthesis, and biological evaluation of novel FAK scaffold inhibitors targeting the FAK-VEGFR3 protein-protein interaction. Eur. J. Med. Chem. 80: 154-166.
36. Bachstetter, A. D., D. M. Watterson, and L. J. Van Eldik. 2014. Target engagement analysis and link to pharmacodynamic endpoint for a novel class of CNS-penetrant and efficacious p38a MAPK inhibitors. J. Neuroimmune Pharmacol. 9: 454-460.
37. Gomella, L. G., D. P. Petrylak, and B. Shayegan. 2014. Current management of advanced and castration resistant prostate cancer. Can. J. Urol. 21(2Suppl. 1): 1-6.